Physician profile
Rachael Bennett
NPI 1134764590
$13,881.73
in general payments reported to CMS, 2019-2025
59 companies · $3,685 in 2025
The $3,685 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,777 · 2022: $2,033 · 2023: $2,858 · 2024: $3,528 · 2025: $3,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,071.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,576.08 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $1,575.47 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $955.10 | 2021-2025 | |
| Lilly USA, LLC | $811.30 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Eisai INC. | $637.90 | 2021-2025 | |
| Pfizer INC. | $636.89 | 2021-2025 | |
| Sk Life Science, INC. | $629.99 | 2021-2025 | Xcopri |
| Lundbeck LLC | $616.66 | 2023-2025 | Rexulti, Vyepti |
| Genentech USA, INC. | $512.06 | 2022-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amneal Pharmaceuticals LLC | $496.03 | 2021-2025 | Rytary, Crexont |
| Amgen INC. | $493.39 | 2021-2024 | Aimovig |
| Biogen, INC. | $482.05 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Argenx US, INC. | $434.54 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $324.59 | 2021-2025 | Nuplazid |
| Genzyme Corporation | $284.29 | 2021-2024 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.